Strategic Partnerships OnCusp has a high-profile investor lineup (Novo Holdings, OrbiMed, F-Prime Capital) and a board strengthened by Novo Holdings and OrbiMed representation, signaling openness to strategic collaborations, co-development deals, and access to global partnering networks.

Clinical-stage Focus As a clinical-stage biopharma with early Phase 1a results for a CDH6-directed ADC (CUSP06) in platinum-refractory ovarian cancer and other solid tumors, there are opportunities to engage in translational research partnerships, late-stage trials, and potential licensing deals as data mature.

Leadership Accessibility Recent C-suite appointments (CFO Anthony Kim, CMO Dimitry Nuyten) indicate leadership growth and a readiness to scale, which can facilitate outbound outreach for financing rounds, strategic alliances, and joint development discussions.

Funding Readiness With a substantial funding base ($125M) and a recent $100M Series A, OnCusp demonstrates financial backing to support co-development, milestone-driven collaborations, and risk-sharing deals with industry partners.

Global Deployment Global investor interest and a focus on rapidly translating preclinical assets into clinically validated cancer therapies position OnCusp as a candidate for international partnerships, licensing in diverse markets, and cross-border clinical program collaborations.